research use only

LOXO-292 (Selpercatinib) RET Inhibitor

Cat.No.S8781

Selpercatinib (LOXO-292, ARRY-192) is a potent and specific RET (c-RET) inhibitor with IC50 values of 1 nM, 2 nM, 2 nM, 4 nM, 2 nM, 2 nM for WT RET, RET V804M, RET V804L, RET A883F, RET M918T and RET S891A respectively.
Jump to

Quality Control

Batch: Purity: 99.96%
99.96

Solubility

In vitro
Batch:

DMSO : 25 mg/mL (47.56 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 525.60 Formula

C29H31N7O3

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 2152628-33-4 -- Storage of Stock Solutions

Synonyms ARRY-192 SMILES CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
RET wt
(Cell-free assay)
1 nM
RET V804M
(Cell-free assay)
2 nM
RET V804L
(Cell-free assay)
2 nM
RET M918T
(Cell-free assay)
2 nM
RET S891A
(Cell-free assay)
2 nM
RET A883F
(Cell-free assay)
4 nM
In vitro

Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor.

References

Applications

Methods Biomarkers Images PMID
Western blot pRET / Flag / cPARP / Actin
S8781-WB-1
33161056

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-24)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06458036 RECRUITING
Differentiated Thyroid Cancer; Pediatric Cancer; Cancer; Cancer, Thyroid
Children's Hospital of Philadelphia
2024-07-29 PHASE2
NCT07010393 NOT_YET_RECRUITING
Thyroid Neoplasms
Fujian Medical University
2025-07-01 PHASE4
NCT04759911 ACTIVE_NOT_RECRUITING
Malignant Thyroid Gland Neoplasm; Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Carcinoma; Thyroid Gland Anaplastic Carcinoma; Thyroid Gland Medullary Carcinoma; Thyroid Gland Papillary Carcinoma; Thyroid Gland Squamous Cell Carcinoma
M.D. Anderson Cancer Center
2021-02-26 PHASE2
NCT02925234 RECRUITING
Cancer; Tumors; Neoplasm; Neoplasia
The Netherlands Cancer Institute
2016-08 PHASE2
NCT07146893 NOT_YET_RECRUITING
Cachexia-Anorexia Syndrome
University of Oklahoma
2026-02-26 EARLY_PHASE1
NCT06195228 RECRUITING
Advanced Thyroid Cancer Patients Who Received Target Therapy
Fudan University
2020-01-01 PHASE4

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map